Beta-hexosaminidase subunit beta is an enzyme that in humans is encoded by the HEXBgene.[5][6][7]
Hexosaminidase B is the beta subunit of the lysosomal enzyme beta-hexosaminidase that, together with the cofactor GM2 activator protein, catalyzes the degradation of the ganglioside GM2, and other molecules containing terminal N-acetyl hexosamines. Beta-hexosaminidase is composed of two subunits, alpha and beta, which are encoded by separate genes. Both beta-hexosaminidase alpha and beta subunits are members of family 20 of glycosyl hydrolases. Mutations in the alpha or beta subunit genes lead to an accumulation of GM2 ganglioside in neurons and neurodegenerative disorders termed the GM2 gangliosidoses. Beta subunit gene mutations lead to Sandhoff disease (GM2-gangliosidosis type II).[7]
Structure
Gene
The HEXB gene lies on the chromosome location of 5q13.3 and consists of 14 exons, spanning 35-40Kb.
Protein
HEXB consists of 556 amino acid residues and weighs 63111Da.
Function
HEXB is one of the two subunits forming β-hexosaminidase which functions as a glycosyl hydrolase that remove β-linked nonreducing-terminal GalNAc or GlcNAc residues in the lysosome.[8] Inability of HEXB will lead toβ-hexosaminidase defect and result in a group of recessive disorders called GM2 gangliosidoses, characterized by the accumulation of GM2 ganglioside.[9]
Clinical significance
Genetic defects in HEXB can result in the accumulation of GM2 ganglioside in neural tissues and two of three lysosomal storage diseases collectively known as GM2 gangliosidosis, of which Sandhoff disease (defects in the β subunit) is the best studied one.[8] Patients present with neurosomatic manifestations. Therapeutic effects of Hex subunit gene transduction have been examined on Sandhoff disease model mice.[10] Intracerebroventricular administration of the modified β-hexosaminidase B to Sandhoff mode mice restored the β-hexosaminidase activity in the brains, and reduced the GM2 ganglioside storage in the parenchyma.[11]
^Sonnino S, Chigorno V (September 2000). "Ganglioside molecular species containing C18- and C20-sphingosine in mammalian nervous tissues and neuronal cell cultures". Biochimica et Biophysica Acta (BBA) - Reviews on Biomembranes. 1469 (2): 63–77. doi:10.1016/s0005-2736(00)00210-8. PMID10998569.
^Gort L, de Olano N, Macías-Vidal J, Coll MA (September 2012). "GM2 gangliosidoses in Spain: analysis of the HEXA and HEXB genes in 34 Tay–Sachs and 14 Sandhoff patients". Gene. 506 (1): 25–30. doi:10.1016/j.gene.2012.06.080. PMID22789865.
Further reading
Mahuran DJ (February 1991). "The biochemistry of HEXA and HEXB gene mutations causing GM2 gangliosidosis". Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1096 (2): 87–94. doi:10.1016/0925-4439(91)90044-A. PMID1825792.
Mahuran DJ (October 1999). "Biochemical consequences of mutations causing the GM2 gangliosidoses". Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1455 (2–3): 105–38. doi:10.1016/S0925-4439(99)00074-5. PMID10571007.
Bolhuis PA, Bikker H (November 1992). "Deletion of the 5'-region in one or two alleles of HEXB in 15 out of 30 patients with Sandhoff disease". Human Genetics. 90 (3): 328–9. doi:10.1007/bf00220096. PMID1487253. S2CID219692.
Banerjee P, Siciliano L, Oliveri D, McCabe NR, Boyers MJ, Horwitz AL, Li SC, Dawson G (November 1991). "Molecular basis of an adult form of beta-hexosaminidase B deficiency with motor neuron disease". Biochemical and Biophysical Research Communications. 181 (1): 108–15. doi:10.1016/S0006-291X(05)81388-9. PMID1720305.
Boose JA, Tifft CJ, Proia RL, Myerowitz R (November 1990). "Synthesis of a human lysosomal enzyme, beta-hexosaminidase B, using the baculovirus expression system". Protein Expression and Purification. 1 (2): 111–20. doi:10.1016/1046-5928(90)90003-H. PMID1967020.
Bikker H, van den Berg FM, Wolterman RA, de Vijlder JJ, Bolhuis PA (February 1989). "Demonstration of a Sandhoff disease-associated autosomal 50-kb deletion by field inversion gel electrophoresis". Human Genetics. 81 (3): 287–8. doi:10.1007/BF00279006. PMID2921040. S2CID39411971.
Bolhuis PA, Oonk JG, Kamp PE, Ris AJ, Michalski JC, Overdijk B, Reuser AJ (January 1987). "Ganglioside storage, hexosaminidase lability, and urinary oligosaccharides in adult Sandhoff's disease". Neurology. 37 (1): 75–81. doi:10.1212/wnl.37.1.75. PMID2948136. S2CID20622020.
1nou: Native human lysosomal beta-hexosaminidase isoform B
1now: Human lysosomal beta-hexosaminidase isoform B in complex with (2R,3R,4S,5R)-2-Acetamido-3,4-Dihydroxy-5-Hydroxymethyl-Piperidinium Chloride (GalNAc-isofagomine)
1np0: Human lysosomal beta-hexosaminidase isoform B in complex with intermediate analogue NAG-thiazoline
1o7a: HUMAN BETA-HEXOSAMINIDASE B
2gjx: Crystallographic structure of human beta-Hexosaminidase A